UBE2C and non-small cell lung carcinoma: These experiments collectively suggest that the SLIT3/UBE2C/Wnt3A axis is crucially involved in promoting the progression of NSCLC, and that inhibition of Wnt signaling could improve the chemotherapy outcomes in NSCLC patients with SLIT3 deficiency.